247 related articles for article (PubMed ID: 32303175)
21. Cotransplantation of NSCs and ethyl stearate promotes synaptic plasticity in PD rats by Drd1/ERK/AP-1 signaling pathway.
Yi L; Ma H; Yang X; Zheng Q; Zhong J; Ye S; Li X; Chen D; Li H; Li C
J Ethnopharmacol; 2024 Mar; 321():117292. PubMed ID: 37806537
[TBL] [Abstract][Full Text] [Related]
22. Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson's disease.
Hansen HH; Fabricius K; Barkholt P; Mikkelsen JD; Jelsing J; Pyke C; Knudsen LB; Vrang N
Brain Res; 2016 Sep; 1646():354-365. PubMed ID: 27233809
[TBL] [Abstract][Full Text] [Related]
23. LPA signaling is required for dopaminergic neuron development and is reduced through low expression of the LPA1 receptor in a 6-OHDA lesion model of Parkinson's disease.
Yang XY; Zhao EY; Zhuang WX; Sun FX; Han HL; Han HR; Lin ZJ; Pan ZF; Qu MH; Zeng XW; Ding Y
Neurol Sci; 2015 Nov; 36(11):2027-33. PubMed ID: 26169757
[TBL] [Abstract][Full Text] [Related]
24. Heat shock protein 60 affects behavioral improvement in a rat model of Parkinson's disease grafted with human umbilical cord mesenchymal stem cell-derived dopaminergic-like neurons.
Zhao C; Li H; Zhao XJ; Liu ZX; Zhou P; Liu Y; Feng MJ
Neurochem Res; 2016 Jun; 41(6):1238-49. PubMed ID: 26758268
[TBL] [Abstract][Full Text] [Related]
25. Neural stem cells transplantation combined with ethyl stearate improve PD rats motor behavior by promoting NSCs migration and differentiation.
Huang J; Yi L; Yang X; Zheng Q; Zhong J; Ye S; Li X; Li H; Chen D; Li C
CNS Neurosci Ther; 2023 Jun; 29(6):1571-1584. PubMed ID: 36924304
[TBL] [Abstract][Full Text] [Related]
26. Effect of Intrastriatal 6-OHDA Lesions on Extrastriatal Brain Structures in the Mouse.
Becker B; Demirbas M; Johann S; Zendedel A; Beyer C; Clusmann H; Haas SJ; Wree A; Tan SKH; Kipp M
Mol Neurobiol; 2018 May; 55(5):4240-4252. PubMed ID: 28616718
[TBL] [Abstract][Full Text] [Related]
27. Vagus nerve stimulation improves locomotion and neuronal populations in a model of Parkinson's disease.
Farrand AQ; Helke KL; Gregory RA; Gooz M; Hinson VK; Boger HA
Brain Stimul; 2017; 10(6):1045-1054. PubMed ID: 28918943
[TBL] [Abstract][Full Text] [Related]
28. Safranal-promoted differentiation and survival of dopaminergic neurons in an animal model of Parkinson's disease.
Zhao Y; Xi G
Pharm Biol; 2018 Dec; 56(1):450-454. PubMed ID: 30354840
[TBL] [Abstract][Full Text] [Related]
29. Alterations of the nigrostriatal pathway in a 6-OHDA rat model of Parkinson's disease evaluated with multimodal MRI.
Perlbarg V; Lambert J; Butler B; Felfli M; Valabrègue R; Privat AL; Lehéricy S; Petiet A
PLoS One; 2018; 13(9):e0202597. PubMed ID: 30188909
[TBL] [Abstract][Full Text] [Related]
30. Human albumin prevents 6-hydroxydopamine-induced loss of tyrosine hydroxylase in in vitro and in vivo.
Zhang LJ; Xue YQ; Yang C; Yang WH; Chen L; Zhang QJ; Qu TY; Huang S; Zhao LR; Wang XM; Duan WM
PLoS One; 2012; 7(7):e41226. PubMed ID: 22815976
[TBL] [Abstract][Full Text] [Related]
31. Rosiglitazone, a PPAR-γ agonist, protects against striatal dopaminergic neurodegeneration induced by 6-OHDA lesions in the substantia nigra of rats.
Lee EY; Lee JE; Park JH; Shin IC; Koh HC
Toxicol Lett; 2012 Sep; 213(3):332-44. PubMed ID: 22842585
[TBL] [Abstract][Full Text] [Related]
32. BDNF-modified human umbilical cord mesenchymal stem cells-derived dopaminergic-like neurons improve rotation behavior of Parkinson's disease rats through neuroprotection and anti-neuroinflammation.
Jiang Z; Wang J; Sun G; Feng M
Mol Cell Neurosci; 2022 Dec; 123():103784. PubMed ID: 36228967
[TBL] [Abstract][Full Text] [Related]
33. Effect of 6-hydroxydopamine treatment on kynurenine aminotransferase-I (KAT-I) immunoreactivity of neurons and glial cells in the rat substantia nigra.
Knyihár-Csillik E; Chadaide Z; Mihály A; Krisztin-Péva B; Fenyo R; Vécsei L
Acta Neuropathol; 2006 Aug; 112(2):127-37. PubMed ID: 16788821
[TBL] [Abstract][Full Text] [Related]
34. Transplanted Neural Stem Cells: Playing a Neuroprotective Role by Ceruloplasmin in the Substantia Nigra of PD Model Rats?
Xiao JJ; Yin M; Wang ZJ; Wang XP
Oxid Med Cell Longev; 2015; 2015():618631. PubMed ID: 26146528
[TBL] [Abstract][Full Text] [Related]
35. Differential Effects of LPS and 6-OHDA on Microglia's Morphology in Rats: Implications for Inflammatory Model of Parkinson's Disease.
Parra I; Martínez I; Ramírez-García G; Tizabi Y; Mendieta L
Neurotox Res; 2020 Jan; 37(1):1-11. PubMed ID: 31478124
[TBL] [Abstract][Full Text] [Related]
36. Increased progenitor cell proliferation and astrogenesis in the partial progressive 6-hydroxydopamine model of Parkinson's disease.
Aponso PM; Faull RL; Connor B
Neuroscience; 2008 Feb; 151(4):1142-53. PubMed ID: 18201835
[TBL] [Abstract][Full Text] [Related]
37. Effects of (-)-sesamin on 6-hydroxydopamine-induced neurotoxicity in PC12 cells and dopaminergic neuronal cells of Parkinson's disease rat models.
Park HJ; Zhao TT; Lee KS; Lee SH; Shin KS; Park KH; Choi HS; Lee MK
Neurochem Int; 2015; 83-84():19-27. PubMed ID: 25747493
[TBL] [Abstract][Full Text] [Related]
38. Human induced pluripotent stem cell-derived neurons improve motor asymmetry in a 6-hydroxydopamine-induced rat model of Parkinson's disease.
Han F; Wang W; Chen B; Chen C; Li S; Lu X; Duan J; Zhang Y; Zhang YA; Guo W; Li G
Cytotherapy; 2015 May; 17(5):665-79. PubMed ID: 25747741
[TBL] [Abstract][Full Text] [Related]
39. Neonatal 6-hydroxydopamine lesioning of rats and dopaminergic neurotoxicity: proposed animal model of Parkinson's disease.
Kostrzewa RM
J Neural Transm (Vienna); 2022 Jun; 129(5-6):445-461. PubMed ID: 35279767
[TBL] [Abstract][Full Text] [Related]
40. High frequency stimulation of subthalamic nucleus results in behavioral recovery by increasing striatal dopamine release in 6-hydroxydopamine lesioned rat.
He Z; Jiang Y; Xu H; Jiang H; Jia W; Sun P; Xie J
Behav Brain Res; 2014 Apr; 263():108-14. PubMed ID: 24462728
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
